Aurinia Pharmaceuticals President Peter Greenleaf Sells 29% Of Holding

Some Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shareholders may be a little concerned to see that the President, Peter Greenleaf, recently sold a substantial US$711k worth of stock at a price of US$5.60 per share. That's a big disposal, and it decreased their holding size by 29%, which is notable but not too bad.

View our latest analysis for Aurinia Pharmaceuticals

The Last 12 Months Of Insider Transactions At Aurinia Pharmaceuticals

The insider, Eun Huh Seoung, made the biggest insider sale in the last 12 months. That single transaction was for US$978k worth of shares at a price of US$10.10 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$5.43. So it may not tell us anything about how insiders feel about the current share price.

Aurinia Pharmaceuticals insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of Aurinia Pharmaceuticals

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 1.3% of Aurinia Pharmaceuticals shares, worth about US$10m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Aurinia Pharmaceuticals Tell Us?

Insiders sold Aurinia Pharmaceuticals shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 1 warning sign with Aurinia Pharmaceuticals and understanding it should be part of your investment process.

But note: Aurinia Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.